Expanding the Use of SGLT2i in Diabetes Beyond Type 2-Reference-Cited by-同舟云学术

Expanding the Use of SGLT2i in Diabetes Beyond Type 2

Published:2023-12-20 Issue:1 Volume:47 Page:50-51
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Giaccari Andrea¹^ORCID

Affiliation:

1. Center for Endocrine and Metabolic Diseases, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, and Università Cattolica del Sacro Cuore, Rome, Italy

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/47/1/50/741628/dci230065.pdf

Reference11 articles.

1. Empagliflozin normalizes fasting hyperglycemia and improves postprandial glucose tolerance in totally pancreatectomized patients: a randomized, double-blind, placebo-controlled crossover study;Baekdal;Diabetes Care,2024

2. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs;Giugliano;Cardiovasc Diabetol,2021

3. Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches;Zhang;Front Pharmacol,2023

4. Effects of sotagliflozin added to insulin in patients with type 1 diabetes;Garg;N Engl J Med,2017

5. Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study;Buse;Diabetes Care,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Renoprotective Mechanisms of Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i)—A Narrative Review;International Journal of Molecular Sciences;2024-06-27